Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-R14014
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Xi'an Jiaotong University
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-R14014 is a therapeutic radiopharmaceutical consisting of the beta-emitting radioisotope Lutetium-177 (177Lu) conjugated to R14014, a targeting ligand directed against Fibroblast Activation Protein (FAP). Developed by The First Affiliated Hospital of Xi'an Jiaotong University, it is being evaluated for the treatment and imaging of advanced solid tumors, including metastatic colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and head and neck squamous cell carcinoma (HNSCC). The agent is typically studied as part of a theranostic pair alongside its Gallium-68 labeled counterpart (68Ga-R14014) to assess biodistribution, dosimetry, and safety in patients with high FAP expression in the tumor stroma. By targeting FAP, which is highly expressed on cancer-associated fibroblasts (CAFs), 177Lu-R14014 aims to deliver localized radiation to the tumor microenvironment, potentially overcoming the limitations of traditional therapies in stroma-rich cancers.
- Other names
- 177Lu-labeled R14014
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 177Lu-R14014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-R14014.